227 related articles for article (PubMed ID: 21107711)
41. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity.
Wong CK; Wong PT; Tam LS; Li EK; Chen DP; Lam CW
J Clin Immunol; 2010 Jan; 30(1):45-52. PubMed ID: 19774453
[TBL] [Abstract][Full Text] [Related]
42. A glance on the role of IL-35 in systemic lupus erythematosus (SLE).
Bahadorian D; Faraj TA; Kheder RK; Najmaldin SK; Haghmorad D; Mollazadeh S; Esmaeili SA
Cytokine; 2024 Apr; 176():156501. PubMed ID: 38290255
[TBL] [Abstract][Full Text] [Related]
43. Pin1-Targeted Therapy for Systemic Lupus Erythematosus.
Wei S; Yoshida N; Finn G; Kozono S; Nechama M; Kyttaris VC; Zhen Zhou X; Tsokos GC; Ping Lu K
Arthritis Rheumatol; 2016 Oct; 68(10):2503-13. PubMed ID: 27159270
[TBL] [Abstract][Full Text] [Related]
44. Upregulated IL-1 Receptor-associated Kinase 1 (IRAK1) in Systemic Lupus Erythematosus: IRAK1 Inhibition Represses Th17 Differentiation with Therapeutic Potential.
Zhou Z; Tian Z; Zhang M; Zhang Y; Ni B; Hao F
Immunol Invest; 2018 Jul; 47(5):468-483. PubMed ID: 29611775
[TBL] [Abstract][Full Text] [Related]
45. Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.
Cai Z; Wong CK; Kam NW; Dong J; Jiao D; Chu M; Lam CW; Tam LS
Lupus; 2015 Oct; 24(12):1257-66. PubMed ID: 25966926
[TBL] [Abstract][Full Text] [Related]
46. Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus.
Mitoma H; Horiuchi T; Kimoto Y; Tsukamoto H; Uchino A; Tamimoto Y; Miyagi Y; Harada M
Int J Mol Med; 2005 Oct; 16(4):609-15. PubMed ID: 16142394
[TBL] [Abstract][Full Text] [Related]
47. IL-17A haplotype confers susceptibility to systemic lupus erythematosus but not to rheumatoid arthritis in Mexican patients.
Montúfar-Robles I; Barbosa-Cobos RE; Alemán-Ávila I; Ramírez-Bello J
Int J Rheum Dis; 2019 Mar; 22(3):473-479. PubMed ID: 30398030
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-32γ: Possible association with the activity and development of nephritis in patients with systemic lupus erythematosus.
Kwon OC; Ghang B; Lee EJ; Hong S; Lee CK; Yoo B; Kim S; Kim YG
Int J Rheum Dis; 2019 Jul; 22(7):1305-1311. PubMed ID: 30941928
[TBL] [Abstract][Full Text] [Related]
49. Exploring the role of interleukin-22 in neurological and autoimmune disorders.
Xin N; Namaka MP; Dou C; Zhang Y
Int Immunopharmacol; 2015 Oct; 28(2):1076-83. PubMed ID: 26311525
[TBL] [Abstract][Full Text] [Related]
50. Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Mende R; Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Lin E; Chang J; Hoi AY; Morand EF; Harris J; Lang T
Front Immunol; 2018; 9():1250. PubMed ID: 29930551
[TBL] [Abstract][Full Text] [Related]
51. [Interleukin-2 signaling pathway regulating molecules in systemic lupus erythematosus].
Guo Q; Chen XY; Su Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1100-1104. PubMed ID: 27987522
[TBL] [Abstract][Full Text] [Related]
52. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus.
Tanaka Y; Saito K; Shirakawa F; Ota T; Suzuki H; Eto S; Yamashita U
J Immunol; 1988 Nov; 141(9):3043-9. PubMed ID: 3262675
[TBL] [Abstract][Full Text] [Related]
53. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
54. Increased interleukin‑9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus.
Ouyang H; Shi Y; Liu Z; Feng S; Li L; Su N; Lu Y; Kong S
Mol Med Rep; 2013 Mar; 7(3):1031-7. PubMed ID: 23291628
[TBL] [Abstract][Full Text] [Related]
55. IL-38: A novel cytokine in systemic lupus erythematosus pathogenesis.
Xu WD; Su LC; Liu XY; Wang JM; Yuan ZC; Qin Z; Zhou XP; Huang AF
J Cell Mol Med; 2020 Nov; 24(21):12379-12389. PubMed ID: 33079487
[TBL] [Abstract][Full Text] [Related]
56. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
[TBL] [Abstract][Full Text] [Related]
57. Cytokine panel and histopathological aspects in the systemic lupus erythematosus.
Avrămescu C; Biciuşcă V; Dăianu T; Turculeanu A; Bălăşoiu M; Popescu SN; Ionete O; Simionescu C
Rom J Morphol Embryol; 2010; 51(4):633-40. PubMed ID: 21103619
[TBL] [Abstract][Full Text] [Related]
58. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
59. Progranulin Mediates Proinflammatory Responses in Systemic Lupus Erythematosus: Implications for the Pathogenesis of Systemic Lupus Erythematosus.
Jing C; Zhang X; Song Z; Zheng Y; Yin Y
J Interferon Cytokine Res; 2020 Jan; 40(1):33-42. PubMed ID: 31804874
[TBL] [Abstract][Full Text] [Related]
60. IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis.
Farah Izati A; Wong KK; Che Maraina CH
Malays J Pathol; 2020 Dec; 42(3):333-347. PubMed ID: 33361714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
